Evidence map›Paper›PMID 34232459›Full record

ArticleFamilial cancer2022

Patient ethnicity and cascade genetic testing: a descriptive study of a publicly funded hereditary cancer program.

Eryn F Braley, Angela C Bedard, Jennifer Nuk, Quan Hong, James E J Bedard, Sophie Sun, Kasmintan A Schrader

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Recommendations for the implementation of genetic testing for metastatic prostate cancer patients in Canada.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022
    Article
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Eryn F Braley *Department of Biology, University of the Fraser Valley, Abbotsford, BC, Canada.
Angela C Bedard *Department of Biology, University of the Fraser Valley, Abbotsford, BC, Canada. angela.bedard@bccancer.bc.ca.ORCID http://orcid.org/0000-0002-1652-5560
Jennifer NukHereditary Cancer Program, BC Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
Quan HongHereditary Cancer Program, BC Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
James E J BedardDepartment of Biology, University of the Fraser Valley, Abbotsford, BC, Canada.
Sophie Sun *Hereditary Cancer Program, BC Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
Kasmintan A Schrader *Hereditary Cancer Program, BC Cancer, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.ORCID http://orcid.org/0000-0002-7413-4314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cascade genetic testing for hereditary cancer is highly accurate and cost-effective for identifying individuals at high risk for cancer; however, not all eligible people utilize this service. While sociodemographic factors related to the uptake of cascade genetic testing, such as age and sex, have been fairly well described in the literature, there is limited data available regarding patient ethnicity. We analyzed four years of testing data for this factor, as well as sex, age and genes tested. The patients were seen by the Hereditary Cancer Program of BC Cancer, which serves the entire population of British Columbia and Yukon, Canada. Patient ethnicity was compared to the 2016 Census data from the same region. Fisher's exact test was conducted to explore the cascade genetic testing uptakes. Chi-square test was used to compare the major ethnicity groups to Census data. There was significant variability in the uptake of cascade genetic testing in the three largest population groups (p < 0.05), with individuals of European ethnic origin overrepresented, individuals of Asian ethnic origin modestly underrepresented, and individuals of North American Indigenous origin considerably underrepresented for cascade genetic testing. The proportions represented compared to those expected from census data were significantly different for these three largest groups (p < 0.01). The majority of cascade genetic tests were for BRCA1/BRCA2 (58.8%), followed by 16.9% for Lynch syndrome genes. Most patients were female (70%), and the mean age of patients was 49 years old. This study provides further insight into uptake of cascade genetic testing by patient ethnicity. Examining patient ethnicity and cascade genetic testing rates helps to identify underserved populations. Our analysis highlights significant underrepresentation of North American Indigenous individuals for hereditary cancer cascade genetic testing, and helps recognize the need for development of culturally-safe alternatives to outreach and service promotion.

Indexed as

Colorectal Neoplasms, Hereditary NonpolyposisEthnicityFemaleGenes, BRCA2Genetic Predisposition to DiseaseGenetic TestingHumansMaleMiddle AgedEthnicityGenetic testingIndigenous healthPredictive testingScreening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.